News & Reports

Have some news you want to share with the Oregon Bio community?  Fill out our submission form.

HemCon Adds Barry Starkman as CEO

June 6, 2012

“I look forward to working with the team in a timely exit from Chapter 11 and then helping HemCon realize its potential as a highly successful and viable enterprise.”

“As we reorganize and restructure with the objective of successfully exiting Chapter 11, Barry is an extremely important addition to the HemCon team. His leadership and expertise will prove valuable in realizing the full potential of our lyophilized plasma program (LyP program), and in developing the optimal strategy for the […]

July 9, 2012 |

Statement by the Press Secretary on H.R. 33, H.R. 2297, and S. 3187

Office of the Press Secretary
July 9, 2012

Statement by the Press Secretary on H.R. 33, H.R. 2297, and S. 3187

On Monday, July 9, 2012, the President signed into law:

H.R. 33, the “Church Plan Investment Clarification Act,” which amends the Securities Act of 1933 to provide specifically for an exemption from SEC requirements in connection with church pension plans participating in collective trust funds;

H.R. 2297, which makes technical amendments to the District of Columbia Code to facilitate development […]

Cluster Cultivation: Oregon may be a sleeping biotech giant

February 28, 2012

Bioscience is one of the fastest growth sectors in the U.S. economy. But by most accounts, Oregon has been a bit tardy to come to the bioscience table.

Up until a decade ago, Oregon’s academic and research universities, small biotechnology and life science firms and health IT existed mainly in silos lacking coordination and collaborative leadership. Average levels of federal and state funding, lackluster private capital and inconsistent infrastructure investments placed Oregon squarely in the bottom half of all […]

Galena Biopharma Strengthens Clinical Management Team

May 3, 2012

“With her outstanding background as an oncology physician and scientist, as well as a biopharmaceutical company executive in small and large companies, Dr. Mazanet brings a wealth of knowledge, expertise and insight to Galena’s management team, ” said Mark J. Ahn, Ph.D., President and CEO. “Her experience and leadership will be instrumental in driving our clinical programs, coordinating with our Scientific Advisory Board and site investigators, and communicating our mission among advocacy groups.”

Dr. Mazanet is an oncologist with […]

Galena Biopharma Announces Expansion of Scientific Advisory Board

May 10, 2012

“Dr. Figlin is a tremendous asset to Galena’s Scientific Advisory Board, as he is a recognized leader and expert in advancing novel cancer therapies,” said Rosemary Mazanet, M.D., Ph.D., Executive Vice President and Chief Medical Officer. “We look forward to his input and guidance as we reach the next level of success with our oncology treatments.”

Dr. Figlin is a prolific researcher known for advancing cancer therapies. His expertise has resulted in the development of novel anti-cancer drugs that […]

MolecularMD Closes $6 Million Series B Financing and Announces Ensuing Growth Initiatives

Dan Snyder, President and COO of MolecularMD commented, “We are grateful for the continued support of Ballast Point Ventures, and we are pleased to be adding oncology-focused Nextech Invest to our investor group. We are well positioned to put the capital to work as we further define our presence in the high growth molecular diagnostics market. MolecularMD has over six years of proven performance, having provided testing in worldwide pivotal trials for several of the most successful targeted cancer therapies […]

New Report Shows Oregon Clinical Trials Benefit State’s Health and Economy

Working in collaboration with Oregon’s university medical schools, hospitals and clinical research centers, biopharmaceutical companies are conducting or have conducted since 1999 more than 2,300 clinical trials of new medicines in the state, a report released today shows.

Clinical trials are critical to the development of new medicines, accounting for up to seven years of the 10 to 15 years required to develop a new drug, according to “Research in Your Backyard: Pharmaceutical Clinical Trials in Oregon.”

The report – compiled by […]

Oregon Bioscience Association Announces Board Officers and Directors for 2012


CONTACT: Dennis McNannay, Executive Director, Oregon Bioscience Assoc., (503) 548-4432
Dianne Danowski Smith, Oregon Bio board member, (503) 201-7019


(Portland, Ore.) — Peter Murray, site executive and vice president for one of Oregon’s largest medical device manufacturers, Welch Allyn, has been appointed chairman of the Oregon Bioscience Association (Oregon Bio) board of directors. Executive committee members include Ryan Dunlap, treasurer, Moss Adams LLP; and Michael Phillips, secretary and […]

TREAT Act Offers Renewed Hope for Patients

Washington, DC (February 15, 2012) – Today, the Biotechnology Industry Organization (BIO) praised Sen. Kay Hagan (D-NC) for introducing the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act. The following statement can be attributed to BIO President and CEO Jim Greenwood:

“The Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act will help unleash the promise of biotechnology to speed life-saving cures, novel medicines and scientific breakthroughs to patients living with debilitating diseases such as cancer, […]

Beam Therapeutics has promoted Chief Scientific Officer Giuseppe "Pino" Ciaramella to president. He will continue to serve as the Cambridge, MA, biotech's CSO, a role he has held for ne [...]

Acceleron Pharma Inc. (NASDAQ: XLRN) announced Thursday that John Quisel, the company's executive vice president and chief business officer, is leaving to become CEO of a venture-backed biotechno [...]

Pentagon spokesman Jonathan Hoffman said that eight of the affected service members returned to the United States from an American military hospital in Germany. [...]

Pfizer isn't giving up in biosims despite early challenges. This week, it unveiled launches to three Roche blockbusters, with two already on the market. The biosims target Roche's Avastin, H [...]

What a difference a day makes in biotech: Yesterday, antibiotics player Summit Therapeutics was riding high after an $8.8 million cash infusion from the U.S. Biomedical Advanced Research and Developme [...]

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing, although don't expect many megadeals. [...]

Bladder cancer may have been the first FDA-approved indication for Tecentriq--as the first PD-1/L1 inhibitor to enter the area--but that doesn't mean the Roche drug can always win there. The Roch [...]

Patients with epithelioid sarcoma previously had no targeted treatment options, but that'll change with Epizyme's approval for Tazverik. The FDA signed off on the drug Thursday, and the comp [...]